The high frequency of the — 6G → A factor IX promoter mutation is the result both of a founder effect and recurrent mutation at a CpG dinucleotide
- 1 March 1995
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 89 (3), 672-674
- https://doi.org/10.1111/j.1365-2141.1995.tb08388.x
Abstract
We report a new Liverpool family with a mild haemophilia B Leyden phenotype caused by a -6G-->A mutation in a CpG dinucleotide in the promoter of the clotting factor IX gene. This mutation had previously been identified in three other U.K. pedigrees and six others worldwide. To investigate whether these mutations were of independent origin, the haplotype was determined for eight polymorphic loci, within or immediately adjacent to the factor IX gene, for nine of the 10 existing patients. Six probands had identical haplotypes, including all four U.K. probands, suggesting that they arose from a common founder. The other three probands differed in haplotype from the common haplotype, and from each other, suggesting that they were independent mutations at this CpG dinucleotide.Keywords
This publication has 12 references indexed in Scilit:
- Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994Nucleic Acids Research, 1994
- Haemophilia B Liverpool: a new British family with mild haemophilia B associated with a — 6 G to A mutation in the factor IX promoterBritish Journal of Haematology, 1993
- Recurrent mutations in the factor IX gene: founder effect or repeat de novo eventsHuman Genetics, 1993
- Hemophilia B Leyden: substitution of thymine for guanine at position - 21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoterBlood, 1993
- An MseI RFLP in the 5’flanking region of the factor IX gene: its use for haemophilia B carrier detection in Caucasian and Thai populationsBritish Journal of Haematology, 1993
- Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutationNature Genetics, 1993
- Recovery from Hemophilia B Leyden: An Androgen-Responsive Element in the Factor IX PromoterScience, 1992
- Evidence that descendants of three founders constitute about 25% of hemophilia B in the united statesGenomics, 1991
- Genetics and molecular biology of haemophilias A and BBlood Coagulation & Fibrinolysis, 1991
- CG dinucleotide transitions in the factor IX gene account for about half of the point mutations in hemophilia B patients: a Seattle seriesHuman Genetics, 1991